January 4, 2007 -- BioCryst received a $102.6 million contract from the HHS to develop flu treatment Permavir; Biogen Idec will acquire Syntonix and its hemophilia drug candidates; Wyeth will partner with Raven biotechnologies to develop cancer drugs; Wyeth also signed a deal with Pharmacopeia to develop its JAK3 inhibitors for immunological conditions; Oscient sold the European marketing rights for antibiotic Factive; Alkermes will develop an inhaled form of an Indevus drug for COPD; Schering-Plough and OraSure will collaborate on an oral test for hepatitis C; Sunesis will out-license its LFA-1 inhibitor program to SARcode; Vical began a pivotal Phase III trial of Allovectin-7 for metastatic melanoma; Medarex received a milestone from ImClone for a solid tumor cancer drug; and Genaera will discontinue any further development of Evizon for wet age-related macular degeneration. Biotech had a very positive day. The Centient Biotech 200™ made up its loss for the entire 2006 year by shooting 1.9% higher. The CBT 200™ gained 73 points to close at 3992. More details...
